BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nasopharyngeal Carcinoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Nasopharyngeal Carcin
 oma\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06118333-2044@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06118333)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy 
 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NP
 C01)\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06118333
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06323239-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06323239)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: SBRT 
 and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngea
 l Carcinoma\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06323239
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956587-2044@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05956587)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally 
 Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcino
 ma and Other Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 56587
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177301-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06177301)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06177301
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05340491-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05340491)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Chemo
 radiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter\, Open-label\, 
 Randomised\, Controlled\, Phase III Trial\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05340491
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676722-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06676722)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: SBRT
  Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent
 /Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06676722
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320963-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07320963)
DESCRIPTION:Toripalimab\, phase 1/2\, Nasopharyngeal Carcinoma.\nStudy: Chi
 damide in Combination With Toripalimab and Anlotinib in Recurrent/Metastat
 ic Nasopharyngeal Carcinoma.\nEstimated primary completion: 28 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07320963
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383780-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06383780)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab in Combination With GP or TPC Regimen for the Treatment of Nasoph
 aryngeal Carcinoma With Bone Metastasis.\nEstimated primary completion: 15
  May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6383780
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06851247-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06851247)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: GAPP 
 Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Mainten
 ance for Nasopharyngeal Carcinoma.\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06851247
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475300-2044@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06475300)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Ca
 rcinoma and Other Solid Tumors\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 475300
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235203-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06235203)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Neoad
 juvant vs Adjuvant in Locally Advanced Recurrent NPC\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06235203
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05484375-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05484375)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Capec
 itabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal 
 Carcinoma After First-line Treatment\nEstimated primary completion: Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 84375
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669611-1972@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06669611)
DESCRIPTION:Camrelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Nab-
 TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metasta
 tic Nasopharyngeal Carcinoma\nEstimated primary completion: 20 November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06669611
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05294172-2581@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagitanlimab: Phase 3 readout est. (NCT05294172)
DESCRIPTION:Tagitanlimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: KL-A
 167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined 
 With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic
  Nasopharyngeal Carcinoma\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05294172
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629597-2817@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT06629597)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Nasopharyngeal Carcinoma.\nStu
 dy: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal C
 arcinoma (TAISHAN-301)\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tambotatug-pelitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0662959
 7
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869227-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05869227)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Maint
 enance Therapy With Toripalimab Combined With Capecitabine/Placebo for Rec
 urrent and Metastatic Nasopharyngeal Carcinoma\nEstimated primary completi
 on: 20 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05869227
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555860-1972@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07555860)
DESCRIPTION:Camrelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Beco
 tatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresecta
 ble Locally Recurrent Nasopharyngeal Carcinoma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07555860
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06781112-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06781112)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: A Ph
 ase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Adva
 nced Nasopharyngeal Carcinoma\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678111
 2
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555860-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07555860)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Becot
 atug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectab
 le Locally Recurrent Nasopharyngeal Carcinoma\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07555860
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331428-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07331428)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: MRG0
 03 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent N
 PC\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07331428
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258979-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07258979)
DESCRIPTION:Toripalimab\, phase 1/2\, Nasopharyngeal Carcinoma.\nStudy: A S
 tudy of YL201 in Combination With Toripalimab and With or Without Cisplati
 n in Nasopharyngeal Carcinoma.\nEstimated primary completion: February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07258979
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258979-2817@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07258979)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Nasopharyngeal Carcinoma.\nS
 tudy: A Study of YL201 in Combination With Toripalimab and With or Without
  Cisplatin in Nasopharyngeal Carcinoma.\nEstimated primary completion: Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tambotatu
 g-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07258979
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388758-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07388758)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Scip
 ibaimab Combined With Tislelizumab in Patients With First-Line Treatment-F
 ailed Recurrent/Metastatic Nasopharyngeal Carcinoma\nEstimated primary com
 pletion: February 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07388758
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388836-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07388836)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Timin
 g Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locall
 y Advanced Nasopharyngeal Carcinoma\nEstimated primary completion: 1 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073888
 36
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373990-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07373990)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Shor
 t-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal C
 arcinoma\nEstimated primary completion: 30 April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07373990
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228079-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06228079)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Adjuv
 ant vs Surgery Only in Early-stage Recurrent NPC\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 oripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06228079
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561763-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20280820
DTEND;VALUE=DATE:20280821
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06561763)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: TPC V
 S. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in th
 e Treatment of Locally Advanced Nasopharyngeal Carcinoma\nEstimated primar
 y completion: 20 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06561763
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06093061-2010@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06093061)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregio
 nally-advanced Nasopharyngeal Carcinoma\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6093061
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712888-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20281126
DTEND;VALUE=DATE:20281127
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06712888)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Torip
 alimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanc
 ed Nasopharyngeal Carcinoma\nEstimated primary completion: 26 November 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06712888
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902713-1972@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07902713)
DESCRIPTION:Camrelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Beco
 tatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metast
 atic Nasopharyngeal Carcinoma\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0790271
 3
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592599-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06592599)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Gemci
 tabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Ass
 ociated Nasopharyngeal Carcinoma(NPC)\nEstimated primary completion: Janua
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0659
 2599
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362979-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290312
DTEND;VALUE=DATE:20290313
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07362979)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Torip
 alimab Combined With Different Platinum-Based Induction Chemotherapy Regim
 ens for Locally Advanced Nasopharyngeal Carcinoma\nEstimated primary compl
 etion: 12 March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07362979
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06912711-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290420
DTEND;VALUE=DATE:20290421
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06912711)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: TN In
 duction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal
  Carcinoma\nEstimated primary completion: 20 April 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06912711
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987123-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06987123)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: TC as
  Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasophary
 ngeal Carcinoma: a Single-arm Clinical Trial\nEstimated primary completion
 : 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripa
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06987123
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110558-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20290814
DTEND;VALUE=DATE:20290815
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07110558)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Radio
 therapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuva
 nt Toripalimab in Nasopharyngeal Carcinoma\nEstimated primary completion: 
 14 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/torip
 alimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07110558
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136519-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07136519)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Torip
 alimab\, Induction Chemotherapy\, Radiation Therapy With Omega-3 for Local
 ly Advanced Nasopharyngeal Carcinoma\nEstimated primary completion: 31 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7136519
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06277050-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20300220
DTEND;VALUE=DATE:20300221
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06277050)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Maint
 enance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone
  in High-risk Nasopharyngeal Carcinoma\nEstimated primary completion: 20 F
 ebruary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06277050
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797881-2044@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07797881)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Nasopharyngeal Carcinoma.\n
 Study: A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Pat
 ients With High-Risk Locally Advanced Nasopharyngeal Carcinoma\nEstimated 
 primary completion: December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07797881
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154069-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07154069)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Adapt
 ive Immunotherapy for Nasopharyngeal Carcinoma\nEstimated primary completi
 on: September 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 oripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07154069
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540390-2018@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07540390)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: GAPP 
 Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Ad
 vanced NPC.\nEstimated primary completion: 31 December 2032. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07540390
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783321-2044@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07783321)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenan
 ce Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-li
 ne Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NP
 C02)\nEstimated primary completion: December 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07783321
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
